[CAS NO. 11042-64-1] γ-Oryzanol
PRODUCTS SPECIFICATIONS [11042-64-1]
DESCRIPTION [11042-64-1]
Overview
| MDL | MFCD00867548 |
|---|---|
| Molecular Weight | 602.89 |
| Molecular Formula | C40H58O4 |
| SMILES | C[C@@H]([C@@]1([H])CC[C@]2(C)[C@]1(C)CCC34C2CCC5[C@@]3(CC[C@H](OC(/C=C/C6=CC(OC)=C(O)C=C6)=O)C5(C)C)C4)CC/C=C(C)\C |
3 Publications Citing Use of MCE
Summary
γ-Oryzanol is a potent DNA methyltransferases ( DNMTs ) inhibitor in the striatum of mice. γ-Oryzanol significantly inhibits the activities of DNMT1 ( IC 50 =3.2 μM), DNMT3a ( IC 50 =22.3 μM).
IC50 & Target
|
DNMT1 3.2 μM (IC 50 ) |
DNMT3A 22.3 μM (IC 50 ) |
In Vitro
γ-Oryzanol significantly inhibits the activities of DNMT1 (IC 50 =3.2 μM), DNMT 3a (IC 50 =22.3 μM) and DNMT 3b (maximum inhibition 57%). In contrast, the inhibitory activity of Ferulic acid, a metabolite of γ-Oryzanol, is much lower than that of γ-Oryzanol. Furthermore, γ-Oryzanol acts as a partial antagonist against ERRγ, which primarily serves as a positive regulator for DNMT1 production, and consequently decreased the activity of DNMT1 [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
The brown rice-specific bioactive component γ-Oryzanol, a mixture of ferulic acid ester and several phytosterols, attenuates the preference for dietary fat via a decrease in hypothalamic endoplasmic reticulum (ER) stress. γ-Oryzanol ameliorates HFD-induced DNA hypermethylation of the promoter region of D2R in the striatum of mice. γ-Oryzanol might regulate levels of DNMTs in a striatum-specific manner. γ-Oryzanol partially decreases ERRγ activity (an approximately 40% reduction of the innate value). Oral administration of γ-Oryzanol to male mice by gavage significantly attenuates the preference for an HFD (93% of the values for vehicle-treated mice), resulting in an apparent attenuation of body weight gain [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT05271045 | National Nutrition and Food Technology Institute |
Diabetes
|
December 1, 2021 | Not Applicable |
Appearance
Solid
Source
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 62.5 mg/mL ( 103.67 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.6587 mL | 8.2934 mL | 16.5868 mL |
| 5 mM | 0.3317 mL | 1.6587 mL | 3.3174 mL |
| 10 mM | 0.1659 mL | 0.8293 mL | 1.6587 mL |
-
1.
Add each solvent one by one: 10% PEG400 >> 10% Tween80 >> 80%saline
Solubility: 10 mg/mL (16.59 mM); Suspended solution; Need ultrasonic
-
2.
Add each solvent one by one: 50% PEG300 >> 50% saline
Solubility: 2.5 mg/mL (4.15 mM); Suspended solution; Need ultrasonic
-
3.
-
4.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2.08 mg/mL (3.45 mM); Suspended solution; Need ultrasonic and warming
-
5.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (3.45 mM); Clear solution
Synonyms